Suraksha Diagnostic Ratios

Suraksha Diagnostic Ltd Ratios

The Suraksha Diagnostic Ltd Ratios page provides a complete fundamental analysis of Suraksha Diagnostic Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Suraksha Diagnostic Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Suraksha Diagnostic Ltd (NSE: SURAKSHA, BSE: 544293) is currently trading at ₹289.60, with a market capitalization of ₹15.36B. As a major player in the Health services sector and Medical/Nursing services industry, Suraksha Diagnostic Ltd remains a key stock for fundamental analysis using Suraksha Diagnostic Ltd Ratios.

Suraksha Diagnostic Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Suraksha Diagnostic Ltd P/E ratio currently stands at 42.19, making it one of the most tracked metrics in Suraksha Diagnostic Ltd Ratios.

Historically, the Suraksha Diagnostic Ltd P/E ratio has shown strong fluctuations:

• 2024: 42.19
• 2023: 0
• 2022: 0
• 2021: 0

The rising Suraksha Diagnostic Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Suraksha Diagnostic Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 6.36.

Historical P/B trend:

• 2024: 6.36
• 2023: 0
• 2022: 0
• 2021: 0

Suraksha Diagnostic Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Suraksha Diagnostic Ltd P/S ratio currently stands at 5.33, an important part of Suraksha Diagnostic Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 5.33
• 2023: 0
• 2022: 0
• 2021: 0

The rising Suraksha Diagnostic Ltd P/S ratio indicates improved revenue valuation by investors.

Suraksha Diagnostic Ltd Price to Cash Flow Ratio (P/CF)

The Suraksha Diagnostic Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 20.26.

Historical Suraksha Diagnostic Ltd Price to Cash Flow Ratio:

• 2024: 20.26
• 2023: 0
• 2022: 0
• 2021: 0

The rising Suraksha Diagnostic Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Suraksha Diagnostic Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Suraksha Diagnostic Ltd EV currently stands at ₹14.1B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 14.1B
• 2023: 0
• 2022: 0
• 2021: 0

Suraksha Diagnostic Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Suraksha Diagnostic Ltd EV/EBITDA ratio is currently 17.04, a key metric in Suraksha Diagnostic Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 17.04
• 2023: 0
• 2022: 0
• 2021: 0

Higher Suraksha Diagnostic Ltd EV/EBITDA suggests premium valuation.

Suraksha Diagnostic Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Suraksha Diagnostic Ltd D/E ratio is currently 0.42, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.42
• 2023: 0.50
• 2022: 0.62
• 2021: 0.68

Suraksha Diagnostic Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Suraksha Diagnostic Ltd ROE currently stands at 16.29%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 16.29
• 2023: 14.09
• 2022: 4.32
• 2021: 0

Suraksha Diagnostic Ltd maintains stable profitability levels.

Suraksha Diagnostic Ltd Ratios Analysis Summary

The Suraksha Diagnostic Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Suraksha Diagnostic Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Suraksha Diagnostic Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.